Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
|Articles|April 23, 2004
FDA grants market approval for Hylaform
Inamed Corp. announced that the U.S. Food and Drug Administration has granted market approval for Hylaform, a hyaluronic acid-based dermal filler that is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds.
Advertisement
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
5